Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

BCYC - Bicycle Therapeutics Plc - ADR


IEX Last Trade
21.515
-0.145   -0.674%

Share volume: 63,602
Last Updated: Fri 30 Aug 2024 09:59:21 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$21.66
-0.15
-0.67%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
25%
Profitability 25%
Dept financing 10%
Liquidity 75%
Performance 15%
Company vs Stock growth
vs
Performance
5 Days
-3.93%
1 Month
-10.97%
3 Months
-1.92%
6 Months
-17.24%
1 Year
-4.99%
2 Year
-15.25%
Key data
Stock price
$21.52
P/E Ratio 
-6.18
DAY RANGE
N/A - $22.32
EPS 
-$3.74
52 WEEK RANGE
$12.54 - $27.24
52 WEEK CHANGE
-$0.03
MARKET CAP 
1.021 B
YIELD 
N/A
SHARES OUTSTANDING 
47.501 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
BETA 
0.91
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$248,733
AVERAGE 30 VOLUME 
$264,438
Company detail
CEO: Kevin Lee
Region: US
Website: http://www.bicycletherapeutics.com/
Employees: 224
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

bicycle therapeutics is a biotechnology company with big ambitions. we aim to revolutionise the pharmaceutical landscape with our disruptive technology and proprietary bicyclic peptide (bicycle®) product platform and to develop transformational new therapies for patients to improve future treatment options in oncology. bicycles, a new class of small molecular weight drug conjugates for oncology and other diseases, are designed to have superior targeting abilities and to be more efficacious and better tolerated than existing drug conjugate modalities. they combine the properties of several therapeutic entities in a single modality, exhibiting the affinity and selective pharmacology associated with antibodies; the distribution kinetics of small molecules, allowing rapid tumor penetration; and the “tuneable” pharmacokinetic half-life and renal clearance of peptides, sparing cytotoxin-payload derived liver and gastrointestinal toxicity. our unique ip is based on the work of scientific foun

Recent news